European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019)
URI dla tej Kolekcji
Przeglądaj
Przeglądanie European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019) według Autor "Bober, Zuzanna"
Aktualnie wyświetlane 1 - 1 z 1
Wyniki na stronie
Opcje sortowania
- PozycjaInfliximab MRI relaxation time in solution(Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bober, Zuzanna; Bar, Piotr; Pasternak, Grzegorz; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, DavidIntroduction. The use of Quantitative Magnetic Resonance Imaging to drug monitoring in vitro or in vivo can provides a powerful means to map the effects of drugs on tissue activity. Aim. The purpose of this study was to measure relaxation time of antibody phantom. For this purpose, infliximab sample was used. Material and methods. The selected methods to detect relaxation time of antibody was Magnetic Resonance Imaging technique. We detected spin-lattice (T1) relaxation time and discuss differences where compare to water. Results. The measurements of spin-lattice (T1) relaxation time showed significant differences. The results obtained in phantom indicate that we can use this result for measurements of relaxation time in vitro. Conclusion. Infliximab is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. We conclude, that Quantitative Magnetic Resonance Imaging can be used to monitor drug effects.